Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
AUTOR(ES)
Neves, Fabia, Menezes Neto, Osvaldo Alves, Polis, Larissa Bueno, Bassi, Sarah Cristina, Brunetta, Denise Menezes, Silva-Pinto, Ana Cristina, Angulo, Ivan Lucena
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2012
RESUMO
OBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values due to microcytosis and hypochromia caused by the thalassemic mutation. The clinical benefit of long-term hydroxyurea treatment is undeniable in sickle cell disease with monitoring of the biological action of the drug being by the complete blood count. The objective of this work is to compare changes in some of the erythrocytic indexes between S/Beta thalassemia and sickle cell anemia patients on long-term hydroxyurea treatment. METHODS: The values of erythrocyte indexes (mean corpuscular volume and mean corpuscular hemoglobin) were compared in a retrospective study of two groups of patients (Sickle cell anemia and S/Beta thalassemia) on hydroxyurea treatment over a mean of six years. RESULTS: The quantitative values of the two parameters differed between the groups. Increases in mean corpuscular volume and reductions in mean corpuscular hemoglobin delay longer in S/Beta thalassemia patients (p-value = 0.018). CONCLUSION: Hematological changes are some of the beneficial effects of hydroxyurea in sickle cell disease as cellular hydration increases and the hemoglobin S concentration is reduced. The complete blood count is the best test to monitor changes, but the interpretation of the results in S/Beta thalassemia should be different.
Documentos Relacionados
- Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
- Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
- Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients
- Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
- Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease